文献速递鼻科

针刺联合蝶腭神经节针刺治疗过敏性鼻炎:随机对照试验

Acupuncture Combined With Sphenopalatine Ganglion Needling for Allergic Rhinitis: A Randomized Controlled Trial.
PubMed 文献 · Int Forum Allergy Rhinol · 2025-12-16

这项多中心随机平行对照试验纳入260例持续性中重度过敏性鼻炎患者,比较药物治疗、针刺、蝶腭神经节针刺及联合治疗8周的疗效。结果显示联合治疗第8周应答率最高(82.54%),且起效最早、疗效持续至随访4周,为过敏性鼻炎提供了非药物选择。

要点

  • 联合治疗第8周应答率82.54%,显著高于针刺、蝶腭神经节针刺和药物组。
  • 联合治疗第2周即出现显著改善(63.49%),起效早于其他组。
  • 与药物相比,联合治疗和针刺的应答率显著更高,蝶腭神经节针刺单用不显著。

核心结论

  • 针刺联合蝶腭神经节针刺对过敏性鼻炎提供更快速、更强效且持续的症状改善。
  • 联合治疗可作为过敏性鼻炎循证的非药物替代方案。

研究设计与样本

  • 多中心、随机、平行对照试验,纳入260例持续性中重度过敏性鼻炎患者。
  • 分为药物组(氯雷他定10 mg/日)、针刺组(每周3次)、蝶腭神经节针刺组(每周1次)和联合组,疗程8周。

主要发现

  • 第8周应答率组间差异显著:联合组82.54%、针刺组71.43%、蝶腭神经节针刺组55.74%、药物组45.31%(p < 0.001)。
  • 联合组第2周即出现最早显著改善(63.49%,p < 0.001),疗效持续至4周随访。
  • 与药物组相比,联合组(RR = 1.90,95%CI 1.40-2.58;p < 0.001)和针刺组(RR = 1.61,95%CI 1.18-2.21;p = 0.003)第8周应答率显著更高。
  • 蝶腭神经节针刺组与药物组相比应答率差异不显著(RR = 1.27,95%CI 0.90-1.79;p = 0.17)。

关键数值与推荐

  • 主要结局为第8周应答率,定义为总鼻症状评分(TNSS)较基线下降≥30%。
  • 次要结局包括TNSS、总鼻外症状评分(TNNSS)、鼻结膜炎生活质量问卷(RQLQ)和视觉模拟量表(VAS)评分的变化。

临床怎么用

  • 对持续性中重度过敏性鼻炎,可考虑针刺联合蝶腭神经节针刺以快速、持续改善症状。
  • 联合治疗方案可作为不愿或不宜长期用药患者的非药物选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although the therapeutic effects of acupuncture and sphenopalatine ganglion (SPG) needling for allergic rhinitis (AR) are well established, evidence for the efficacy of their combination remains limited. METHODS: In this multicenter, randomized, parallel-controlled trial, 260 patients with persistent moderate-to-severe AR were assigned to 8 weeks of pharmacotherapy (MED; loratadine 10 mg/day), acupuncture (ACU; 3 sessions/week), sphenopalatine ganglion needling (SPG-N; 1 session/week), or combination therapy (COM, which received both acupuncture and SPG needling). The primary outcome was the response rate (≥30% reduction in total nasal symptom score [TNSS]) at Week 8. Secondary outcomes included changes in TNSS, total non-nasal symptom score (TNNSS), rhinoconjunctivitis quality of life questionnaire (RQLQ), and visual analogue scale (VAS) scores from baseline to Weeks 2, 4, 8, and the 4-week follow-up. RESULTS: At Week 8, response rates differed significantly among groups (COM: 82.54%; ACU: 71.43%; SPG-N: 55.74%; MED: 45.31%; p < 0.001) and were sustained at the 4-week follow-up. The COM showed the earliest significant improvement at Week 2 (63.49%, p < 0.001). Compared to MED, both COM (relative risk [RR] = 1.90, 95% confidence interval [CI], 1.40-2.58; p < 0.001) and ACU (RR = 1.61, 95% CI, 1.18-2.21; p = 0.003) were associated with significantly higher response rates at Week 8, whereas SPG-N was not (RR = 1.27, 95% CI, 0.90-1.79; p = 0.17). CONCLUSION: This study demonstrated that acupuncture combined with SPG needling provides more rapid, robust, and sustained symptomatic improvement in AR, offering an evidence-based non-pharmacologic alternative for AR management.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Liu S, Shen Y, Meng X, et al. Acupuncture Combined With Sphenopalatine Ganglion Needling for Allergic Rhinitis: A Randomized Controlled Trial. Int Forum Allergy Rhinol. 2025. PMID: 41403227. doi:10.1002/alr.70085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。